| Title |
Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study |
| Protocole ID |
FORUM |
| ClinicalTrials.gov ID |
NCT02670564 |
| Cancer Type(s) |
Pediatric |
| Phase |
Phase IV |
| Stage |
|
| Study Type |
Genetic |
| Drug |
|
| Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 HOPITAL DE MONTREAL POUR ENFANTS
1001 boul. Décarie , Montréal, QC, H4A 3J1
|
| City |
Montréal |
| Principal Investigator |
Dr. David Mitchell
|
| Coordinator |
Samira Mezziani
514-412-4400 poste 22930
|
| Status |
Recruiting |
| Activation Date |
|
| Eligibility Criteria |
-
age at time of screening less than 18 years old
-
Patients with ALL (except for patients with B-ALL)
-
indication for allogeneic HSCT
-
complete remission (CR) before HSCT
-
written consent of the parents (legal guardian) and, if necessary, the minor patient via "Informed Consent Form"
-
no pregnancy
-
no secondary malignancy
-
no previous HSCT
-
HSCT is performed in a study participating centre
|
| Exclusion Criteria |
-
Non Hodgkin-Lymphoma
-
ALL with extramedullary involvement with indication for TBI
-
CNS involvement at the timepoint of screening
-
Trisomy 21
-
The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
-
No consent is given for saving and propagation of anonymous medical data for study reasons
-
Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders)
-
Karnofsky / Lansky score < 50%
-
Subjects unwilling or unable to comply with the study procedures
|
| |
|
Groupe d'étude en oncologie du Québec